Botox wastage: Medicare pays for unused drug in single vials

Why This Topic Matters

Practices that administer Botox under Medicare need to know how the discarded portion of a single-use vial is handled so claims are filed consistently and documentation is maintained appropriately. The article also highlights manual changes that may affect operational billing workflows and compliance review.

Article Sections

1. Medicare policy update on discarded drugs

   Introduces the Medicare change affecting unused portions of single-use vials and explains the general policy update referenced in the transmittal. It also frames why the change matters for practices that administer injectable drugs or biologicals.

2. Botox as the primary example

   Discusses why Botox is the main drug affected in ophthalmology and describes the operational context for scheduling and vial usage. The section focuses on the overall billing scenario and the medical settings in which the guidance is relevant.

3. Claims reporting and documentation guidance

   Summarizes the manual sections and claim-reporting workflow discussed in the article, including documentation expectations and handling of discarded amounts across one or more patients. It also notes carrier-specific reporting considerations.

4. Competitive Acquisition Program (CAP)

   Covers the separate Medicare guidance for CAP participants and the related emphasis on minimizing unused drug or biological portions. This section addresses the broader compliance expectations tied to CAP administration and vendor responsibilities.

5. CPT-ICD-9 links for Botox treatment

   Provides a brief reference linking Botox treatment to diagnosis and procedure coding examples mentioned at the end of the article. It serves as a short coding cross-reference section.